For patients

For patients

TREATswitzerland at a glance

Why?Investigation of medical care and response to treatment
Who?Patients with moderate and severe neurodermatitis aged 12 and over
How?Review of the patient information and consent to the registry study
What?Completing the questionnaires
Where?At the dermatology clinic/practice
When?At the start, after 3 and 6 months, subsequently at three or six-month intervals, during routine examinations

1. Selection of study participants

The TREATswitzerland registry study is enrolling patients who suffer from moderate or severe atopic dermatitis (neurodermatitis) and are 12 years or older.

2. Objectives

3. General information on the patient registry

4. Voluntary participation

Participation in the registry study is voluntary.

Those who do not want to participate in this research project or who subsequently want to withdraw their participation do not have to justify this. Treatment/care is guaranteed regardless of this decision.

5. Study procedure

6. Obligations of the study participants

Patients taking part in this research project are asked:

7. Benefits for the participants

Participants will not personally gain any direct benefit from participation. However, the results may be important for the future treatment of all neurodermatitis patients.

8. Risks and inconveniences

9. New findings

The study sites inform the participants about any new findings that may influence the benefit or safety of the therapy. After completion of the research project, the participants will receive a summary of the overall results.

10. Data confidentiality

For this research project, personal and health data are collected and processed, partly in automated form. During data collection, the data is encrypted. Encryption means that all reference data that could identify the participants (name, date of birth etc.) is deleted and replaced with a code. People who do not have access to this code list cannot identify you. The code list always remains at the study site (at the practice/hospital).

All data protection requirements are strictly observed. It is possible that the data must be transmitted in encrypted form, for example for a publication, and can be made available to other researchers.

The data could be important for answering other questions at a later date and could be sent to another database in Switzerland or abroad for this purpose and used for as yet undefined investigations (further use). This other database must comply with the same standards as the database for this project.

11. Costs

Participation in the registry study does not incur any additional costs for the participants or their health insurers.

Principal Investigator
Prof. Dr. med. Dagmar Simon